Home » Publications » LMQ adjuvant » Enhancing Immunogenicity of a Thermostable, Efficacious SARS-CoV-2 Vaccine Formulation through Oligomerization and Adjuvant Choice

Enhancing Immunogenicity of a Thermostable, Efficacious SARS-CoV-2 Vaccine Formulation through Oligomerization and Adjuvant Choice

Khan MS, Jakob V, Singh R, et al. Published online December 12, 2023. doi:10.3390
Share on linkedin
Share on reddit
Share on facebook
Share on twitter
Share on email

VFI headquarters and Geneva laboratories

Rue du Champ-Blanchod 4
1228 Plan-les-Ouates
Switzerland

VFI Lausanne laboratories

Route de la Corniche 5
1066 Epalinges
Switzerland

contact@vformulation.org
VFI on LinkedIn

© 2024 Vaccine Formulation Institute